Compare Sanofi SA (SNY) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Sanofi SA trades at $43.14 (market cap $104.06B), while Direxion Daily Semiconductor Bear 3X Shares trades at $43.74. The key difference: Sanofi SA pays a 5.61% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| SNY | SOXS | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $1.29K |
52-Week Low | $41.33 | $32.50 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, declined 4.86% to $44.09 amid bearish technical signals with 18 sell indicators versus 2 buy signals. The fund benefits from semiconductor sector weakness but faces volatility due to its leveraged inverse structure. Recent corporate actions include a 1:10 stock split scheduled for July 2026 and a $0.04 dividend payment in June 2026.
The outlook remains challenging with technical indicators signaling bearish momentum. While SOXS offers tactical opportunities during semiconductor downturns, its leveraged nature poses significant risks for long-term investors. Key risks include AI hardware demand resilience and rapid market reversals that could erode value quickly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
